Citadel Advisors’s The Oncology Institute TOI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.23M Buy
1,703,000
+1,252,700
+278% +$3.84M ﹤0.01% 4265
2025
Q4
$1.6M Buy
450,300
+369,900
+460% +$1.37M ﹤0.01% 6365
2025
Q3
$281K Buy
+80,400
New +$275K ﹤0.01% 10530

Other funds holding TOI

Citadel Advisors's TOI Position: Q1 2026 in Review

Citadel Advisors opened a new position in The Oncology Institute (TOI) in Q1 2026: 608,267 shares worth $1.87M. The stake represents ﹤0.01% of the portfolio and ranks #6215 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TOI as recently as Q3 2025.

Citadel Advisors first reported a position in TOI in Q1 2021 and has held it in 11 quarters since. The position peaked at $14.6M in Q3 2021. 115 funds tracked by Wall St. Rank hold TOI as of Q1 2026.

  • Citadel Advisors held 608,267 shares of The Oncology Institute worth $1.87M as of Q1 2026.
  • The Oncology Institute was a new Citadel Advisors position in Q1 2026.
  • The Oncology Institute made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6215 holding.
  • Citadel Advisors first reported a position in The Oncology Institute in Q1 2021 and has held it in 11 quarters since.
  • Citadel Advisors's The Oncology Institute position peaked at $14.6M in Q3 2021.
  • 115 funds tracked by Wall St. Rank held The Oncology Institute as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.